What technology was used in this study?

It uses comprehensive analysis of microRNAs in urinary extracellular vesicles (exosomes) evaluated by a machine learning model.

What is the diagnostic accuracy of the study?

It achieved high diagnostic accuracy with an AUC of 0.937, sensitivity of 85.6%, and specificity of 94.4%.

When will this test be available?

It is currently in the research stage. A timeline for general availability has not been set, pending large-scale clinical trials and regulatory approval.

AI News NQ Analysis

Craif Announces Joint Research Results on Early Detection of Gynecological Tumors Using Urinary microRNA at the 78th Annual Congress of the Japan Society of Obstetrics and Gynecology

NQ Score 0/100

N1 Content Completeness 9

AI Summary (NQ-processed)

Craif Inc. announced joint research results with Hokkaido University on early detection of gynecological tumors using urinary microRNA at the 78th Annual Congress of the Japan Society of Obstetrics and Gynecology. The study demonstrated the potential of a highly accurate, non-invasive screening method.

AI Analysis

Frequently Asked Questions

Q: What technology was used in this study?: A: It uses comprehensive analysis of microRNAs in urinary extracellular vesicles (exosomes) evaluated by a machine learning model.
Q: What is the diagnostic accuracy of the study?: A: It achieved high diagnostic accuracy with an AUC of 0.937, sensitivity of 85.6%, and specificity of 94.4%.
Q: When will this test be available?: A: It is currently in the research stage. A timeline for general availability has not been set, pending large-scale clinical trials and regulatory approval.